Population pharmacokinetics and dose optimization of ceftazidime in critically ill children

ObjectiveThe aim of this study was to develop a population pharmacokinetic model for ceftazidime in critically ill children in the pediatric intensive care unit (PICU) and optimize an appropriate dosing regimen for this population.MethodsWe performed a prospective pharmacokinetic study on critically...

Full description

Saved in:
Bibliographic Details
Main Authors: Mengting Li, Liuliu Gao, Zuo Wang, Lingkong Zeng, Chen Chen, Jun Wang, Sichan Li, Maochang Liu, Yang Wang
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-11-01
Series:Frontiers in Pharmacology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2024.1470350/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1846151822706737152
author Mengting Li
Liuliu Gao
Zuo Wang
Lingkong Zeng
Chen Chen
Jun Wang
Sichan Li
Maochang Liu
Yang Wang
author_facet Mengting Li
Liuliu Gao
Zuo Wang
Lingkong Zeng
Chen Chen
Jun Wang
Sichan Li
Maochang Liu
Yang Wang
author_sort Mengting Li
collection DOAJ
description ObjectiveThe aim of this study was to develop a population pharmacokinetic model for ceftazidime in critically ill children in the pediatric intensive care unit (PICU) and optimize an appropriate dosing regimen for this population.MethodsWe performed a prospective pharmacokinetic study on critically ill children aged 0.03–15 years. A population pharmacokinetic model was developed using the NLME program. Statistical and graphical methods were used to assess the stability and predictive performance of the model. Monte Carlo simulations were conducted to determine the optimal ceftazidime dosing regimen to achieve 70% fT > minimum inhibitory concentration (MIC).ResultsThis study included 88 critically ill children and 100 ceftazidime serum concentrations. The pharmacokinetic characteristics of ceftazidime were best described by a one-compartment linear elimination model. The weight and estimated glomerular filtration rate (eGFR) were determinant covariates for the clearance (CL) of ceftazidime. The recommended ceftazidime dosage regimens achieved a probability of target attainment (PTA) >90% for critically ill children at MIC values of 2, 4, and 8 mg/L. For bacterial infection at an MIC of 16 mg/L, it is difficult to achieve effective pharmacodynamic (PD) targets in vivo with the commonly used dose of ceftazidime.ConclusionThe population pharmacokinetic model of ceftazidime was established in critically ill children. Based on this model, we recommend evidence-based, individualized dosing regimens for subgroups with different weights and renal functions. The current daily dosage for children adequately meets the treatment requirements for MICs of 2, 4, and 8 mg/L, while for bacterial infection at an MIC of 16 mg/L, an elevated dosage regimen may be required.Clinical Trial Registrationhttps://www.medicalresearch.org.cn/login, Identifier MR-42-22-000220.
format Article
id doaj-art-42ca941e56004d71bcbaa51059b40c20
institution Kabale University
issn 1663-9812
language English
publishDate 2024-11-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Pharmacology
spelling doaj-art-42ca941e56004d71bcbaa51059b40c202024-11-27T04:34:01ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122024-11-011510.3389/fphar.2024.14703501470350Population pharmacokinetics and dose optimization of ceftazidime in critically ill childrenMengting Li0Liuliu Gao1Zuo Wang2Lingkong Zeng3Chen Chen4Jun Wang5Sichan Li6Maochang Liu7Yang Wang8Department of Clinical Pharmacy, Wuhan Children’s Hospital (Wuhan Maternal and Child Healthcare Hospital), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaDepartment of Clinical Pharmacy, Wuhan Children’s Hospital (Wuhan Maternal and Child Healthcare Hospital), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaDepartment of Neonatology, Wuhan Children’s Hospital (Wuhan Maternal and Child Healthcare Hospital), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaDepartment of Neonatology, Wuhan Children’s Hospital (Wuhan Maternal and Child Healthcare Hospital), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaDepartment of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaDepartment of Clinical Pharmacy, Wuhan Children’s Hospital (Wuhan Maternal and Child Healthcare Hospital), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaDepartment of Clinical Pharmacy, Wuhan Children’s Hospital (Wuhan Maternal and Child Healthcare Hospital), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaDepartment of Clinical Pharmacy, Wuhan Children’s Hospital (Wuhan Maternal and Child Healthcare Hospital), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaDrug Clinical Trial Institution, Wuhan Children’s Hospital (Wuhan Maternal and Child Healthcare Hospital), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaObjectiveThe aim of this study was to develop a population pharmacokinetic model for ceftazidime in critically ill children in the pediatric intensive care unit (PICU) and optimize an appropriate dosing regimen for this population.MethodsWe performed a prospective pharmacokinetic study on critically ill children aged 0.03–15 years. A population pharmacokinetic model was developed using the NLME program. Statistical and graphical methods were used to assess the stability and predictive performance of the model. Monte Carlo simulations were conducted to determine the optimal ceftazidime dosing regimen to achieve 70% fT > minimum inhibitory concentration (MIC).ResultsThis study included 88 critically ill children and 100 ceftazidime serum concentrations. The pharmacokinetic characteristics of ceftazidime were best described by a one-compartment linear elimination model. The weight and estimated glomerular filtration rate (eGFR) were determinant covariates for the clearance (CL) of ceftazidime. The recommended ceftazidime dosage regimens achieved a probability of target attainment (PTA) >90% for critically ill children at MIC values of 2, 4, and 8 mg/L. For bacterial infection at an MIC of 16 mg/L, it is difficult to achieve effective pharmacodynamic (PD) targets in vivo with the commonly used dose of ceftazidime.ConclusionThe population pharmacokinetic model of ceftazidime was established in critically ill children. Based on this model, we recommend evidence-based, individualized dosing regimens for subgroups with different weights and renal functions. The current daily dosage for children adequately meets the treatment requirements for MICs of 2, 4, and 8 mg/L, while for bacterial infection at an MIC of 16 mg/L, an elevated dosage regimen may be required.Clinical Trial Registrationhttps://www.medicalresearch.org.cn/login, Identifier MR-42-22-000220.https://www.frontiersin.org/articles/10.3389/fphar.2024.1470350/fullpediatric intensive care unitchildrenceftazidimepopulation pharmacokineticsdose optimization
spellingShingle Mengting Li
Liuliu Gao
Zuo Wang
Lingkong Zeng
Chen Chen
Jun Wang
Sichan Li
Maochang Liu
Yang Wang
Population pharmacokinetics and dose optimization of ceftazidime in critically ill children
Frontiers in Pharmacology
pediatric intensive care unit
children
ceftazidime
population pharmacokinetics
dose optimization
title Population pharmacokinetics and dose optimization of ceftazidime in critically ill children
title_full Population pharmacokinetics and dose optimization of ceftazidime in critically ill children
title_fullStr Population pharmacokinetics and dose optimization of ceftazidime in critically ill children
title_full_unstemmed Population pharmacokinetics and dose optimization of ceftazidime in critically ill children
title_short Population pharmacokinetics and dose optimization of ceftazidime in critically ill children
title_sort population pharmacokinetics and dose optimization of ceftazidime in critically ill children
topic pediatric intensive care unit
children
ceftazidime
population pharmacokinetics
dose optimization
url https://www.frontiersin.org/articles/10.3389/fphar.2024.1470350/full
work_keys_str_mv AT mengtingli populationpharmacokineticsanddoseoptimizationofceftazidimeincriticallyillchildren
AT liuliugao populationpharmacokineticsanddoseoptimizationofceftazidimeincriticallyillchildren
AT zuowang populationpharmacokineticsanddoseoptimizationofceftazidimeincriticallyillchildren
AT lingkongzeng populationpharmacokineticsanddoseoptimizationofceftazidimeincriticallyillchildren
AT chenchen populationpharmacokineticsanddoseoptimizationofceftazidimeincriticallyillchildren
AT junwang populationpharmacokineticsanddoseoptimizationofceftazidimeincriticallyillchildren
AT sichanli populationpharmacokineticsanddoseoptimizationofceftazidimeincriticallyillchildren
AT maochangliu populationpharmacokineticsanddoseoptimizationofceftazidimeincriticallyillchildren
AT yangwang populationpharmacokineticsanddoseoptimizationofceftazidimeincriticallyillchildren